Lenalidomide maintenance significantly improves survival in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).
Mark L. Fuerst
Among pediatric acute lymphoblastic leukemia patients who have favorable prognosis, an attempt to reduce the burden of chemotherapy by using lower intensity delayed intensification failed to show better outcomes.
Older patients with AML survive longer after receiving an allogeneic stem cell transplant if they are initially treated with CPX-351 liposome injection instead of the standard “7+3” chemotherapy with cytarabine and daunorubicin.
A combination of the checkpoint inhibitors nivolumab and ipilimumab continues to demonstrate superior clinical activity vs ipilimumab monotherapy in treatment-naive patients with advanced melanoma.
Adding bortezomib to bendamustine/rituximab significantly improves complete remission rates in previously untreated high-risk follicular lymphoma, according to a new study.
A Web-based application allows for earlier detection of relapse among patients with advanced lung cancer, improving survival by 7 months.
Among breast cancer survivors, black women are far less likely to receive BRCA testing and preventive surgery than white or Hispanic women.
A combination of the endoglin antibody TRC105 and pazopanib shows promising activity in patients with advanced soft-tissue sarcoma, particularly angiosarcoma.
A novel first-in-class antibody can significantly extend median survival when added to standard chemotherapy for patients with advanced gastric cancer.
Postmenopausal women with early breast cancer benefit from extending AI therapy with letrozole from 5 to 10 years, and show no worsening of quality of life.